News

The Harvard Brain Tissue Resource Center at McLean Hospital, also known as the Brain Bank, has signed a new, potentially $12.8 million contract with the National Institutes of Health (NIH) that allows it to continue to collect brain specimens from donors with a range of neurological and psychiatric disorders, including…

The U.S. Food and Drug Administration (FDA) has approved Vumerity (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive disease (SPMS). Vumerity (previously known as ALKS 8700) was developed by Alkermes…

A new Phase 3 clinical trial to explore the safety and efficacy of Mapi Pharma’s once-a-month injectable formulation of glatiramer acetate — named GA Depot — has started enrolling patients with relapsing multiple sclerosis (MS). The trial (NCT04121221) is expected to enroll approximately 960 participants, 18 to 55…

Physical symptoms and poorer coping mechanisms are major risk factors for unemployment in younger and older people with multiple sclerosis (MS), while psychological problems have the greatest impact in middle-aged patients’ unemployment, a study suggests. These findings highlight that unemployment risk factors vary with age and call for interventions…

Exposure to UV-B light prevented multiple sclerosis (MS)-like symptoms in a mouse model regardless of the presence of vitamin D or the vitamin D receptor, a new study discovered.  The study, “UV light suppression of EAE (a mouse…

People with multiple sclerosis (MS) tend to have low levels in their blood serum of certain antibodies that can protect against infection, regardless of whether they are using a disease-targeted therapy or not, a study reports. These levels were not so low as to risk infection on their own,…

The transcription factor family AP-1 is crucial for the proper activation of immune T-cells, a new study shows, and this finding may have important implications for autoimmune diseases such as multiple sclerosis. The study, titled “AP-1 activity induced by co-stimulation is required for chromatin opening during…

Depleting microbes in the gut of mice led to an altered fear response, changes in gene expression in brain immune cells and changes in brain chemistry — returning to a more normal state after their gut microbes were restored, but only if done early in life, a study…

Higher intellectual ability and physical activity during childhood and adolescence may help protect against the development of cognitive impairment in people with multiple sclerosis (MS), an Italian study suggests. These findings, though preliminary, suggest that intellectual enrichment and early-life physical activity may reduce the likelihood of developing cognitive deficits…

A twice-daily dosing schedule and side effects like nausea and flushing are key reasons why more than 10% of multiple sclerosis (MS) patients followed for a year stopped using Tecfidera (dimethyl fumarate) as prescribed, a single-site study reports. Adherence to treatment is key to patients’ health, and doctors should not…

SARM1 inhibitors are a potential oral treatment to slow disease progression in neurodegenerative diseases like multiple sclerosis (MS), according to preclinical results that show the inhibitors protect nerve cells from damage in mice and cell cultures. Researchers at Disarm Therapeutics presented the findings in a poster titled “…

Vitalis is planning to open a pivotal clinical trial into its new formulation of fumarate, called VTS-72, that has shown promise in easing flushing — a common and troublesome side-effect of Tecfidera (dimethyl fumarate), an oral treatment for relapsing-remitting multiple sclerosis (RRMS). The company announced plans to…

The levels of neurofilament light chain (NfL) and chitinase3-like1 (CHI3L1) in the cerebrospinal fluid — the liquid that surrounds the brain and spinal cord — serve as respective biomarkers of disease activity and progression in multiple sclerosis (MS), a study reports. Measuring levels of both proteins also helps to…

Some 4,000 science experts from 126 countries will gather at the 24th World Congress of Neurology (WCN 2019) to discuss cutting-edge research, including advances in diseases such as multiple sclerosis (MS). Hosted by the World Federation of Neurology (WFN) and the Emirates Neurology Society, the conference will run Oct. 27–31, in Dubai,…

Endothelin-1 (ET-1) — a molecule with potent blood vessel-narrowing (vasoconstrictive) properties — may be used as a biomarker of severity for optic neuritis in people with multiple sclerosis (MS), a small Italian study suggests. The molecule also may be a potential indicator of patients’ failure to recover…

Long-term treatment with Gilenya (fingolimod) in patients with relapsing forms of multiple sclerosis (MS) is safe and effective, results from a Phase 3 trial show. Trial findings were reported in the study, “Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results,” published in…

A genetic variant in the galanin gene (GAL) appears to be a risk factor for more severe multiple sclerosis (MS), nearly doubling the risk of rapidly progressive disease, particularly in patients whose disease onset occurs…

The National Multiple Sclerosis Society (NMSS) awarded $14.6 million in grants supporting 43 new and multiyear research projects into multiple sclerosis (MS), part of a projected $36 million investment in disease research for 2019, the society announced on its website. Funded projects include research into new ways of halting progressive MS, the…

With more high-efficacy therapies becoming available, is it now inappropriate to prescribe older injectables — interferon beta and glatiramer acetate — to people with active relapsing multiple sclerosis (MS)? This question was at the core of what was called a “burning debate” at this year’s European Committee…

The MS MindShift: A New View of MS initiative is continuing its travels to raise awareness and educate people about brain health in multiple sclerosis (MS), with the next stop for its “Brain Bulb” hot air balloon the Owl-O-Ween Hot Air Balloon Festival in Kennesaw, Georgia. This weekend’s event, Oct. 18–19,…

The levels of the inflammatory molecule interleukin-22 (IL-22) may be used as a potential biomarker to evaluate disease severity and the effectiveness of treatments in patients with relapsing-remitting multiple sclerosis (RRMS), a new study shows. The study, “Impact of interferon β-1b, interferon β-1a and fingolimod therapies on serum…

Newer disease-modifying treatments for multiple sclerosis (MS) are effective but also known to carry a greater risk of infections in a patient group already more likely to be troubled by infections — and this higher risk is particularly evident in treatment with rituximab, a DMT often used off-label in…

Early treatment with Tysabri (natalizumab) of patients with aggressive pediatric-onset multiple sclerosis is highly effective at achieving disease activity-free status and preventing cognitive decline, a new study shows. The study, “No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab,”…

The National Multiple Sclerosis Society awarded more than $339,000 to Clene Nanomedicine to support clinical tests into its lead candidate CNM-Au8 in treating multiple sclerosis (MS) by protecting nerve cells and restoring myelin. The grant was awarded under the National MS Society’s Fast Forward program, which aims…

Ofatumumab, an investigational B-cell therapy being developed by Novartis, demonstrated encouraging results in lowering relapse rates and active brain lesions in people with relapsing multiple sclerosis (MS) enrolled in the ASCLEPIOS trials. For Stephen L. Hauser, MD, an investigator in the ASCLEPIOS trials, these results represent a…

Immunic Therapeutics announced that a Phase 2 clinical trial of IMU-838, its experimental oral therapy for relapsing-remitting multiple sclerosis (RRMS), is fully enrolled ahead of schedule. The trial, called EMPhASIS, also exceeded its target number of participants: Immunic set an initial recruitment goal of 195 patients by mid-2020, and enrolled 210…

Occasional, or rotating, night shift work, even if done over a decade, does not seem to be directly linked to a higher risk of multiple sclerosis. But working nights for more than 20 years — and likely beginning such shifts early in a career — carries an almost three…

Metformin, a common diabetes treatment that works to mimic dietary fasting, was seen to promote remyelination in the stem cells of elderly rats, suggesting it may be useful in treating multiple sclerosis. “Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells” was published in…

Prescriptions of two multiple sclerosis (MS) treatments —  Merck KGaA‘s Mavenclad (cladribine) and Roche‘s Ocrevus (ocrelizumab) — have been rising in Europe over the past six months, bolstered by greater market access and compassionate use programs, according to a survey of 250 EU neurologists run…

Through its Stop MS Appeal campaign, the United Kingdom’s MS Society seeks to raise £100 million (almost $125 million) within the next decade to advance research and treatments that will stop multiple sclerosis (MS) progression. Over the next three months, the organization will run an extensive advertising campaign…